At the Alz Assn AAIC meeting this week, the data from the donanemab phase 3 clinical trial was presented. The paper was published online by JAMA, and so far is listed as “free” but is copyrighted.
Since our own Seattle Times made it a front page item, other news outlets have descriptions, and JAMA published FOUR editorials [?!#? Manly & Deters; Rabinovici & La Joie; Rosenthal; Widera, Brangman & Chin] this will be a short.
This blog started reporting on donanemab human results in 2020. Subsequent posts appeared in 2021, when donanemab missed its predefined clinical endpoints in NEJM (at first glance, the IARDS curves don’t look much different). Evidently the company thought of pulling back on further development, but with the FDA approving aducanumab (not without controversy), the company was said to have changed its course to press ahead. A blog posting here two months ago (May 2023) explored donanemab’s amyloid-beta responses by PET scan measures.
So, AD still gets worse and is not stopped, but let’s still hope for the best!
